Nazione: Nuova Zelanda
Lingua: inglese
Fonte: Medsafe (Medicines Safety Authority)
Estradiol valerate 2mg; Estradiol valerate 2mg
Bayer New Zealand Limited
Estradiol valerate 2 mg
2 mg
Coated tablet
Active: Estradiol valerate 2mg Excipient: Calcium carbonate Glycerol as glycerol 85% Glycol montanate Indigo carmine Lactose monohydrate Macrogol 6000 Magnesium stearate Maize starch Povidone as polyvidone 25000 Purified talc Sucrose Titanium dioxide Active: Estradiol valerate 2mg Excipient: Calcium carbonate Glycol montanate Lactose monohydrate Macrogol 6000 Magnesium stearate Maize starch Povidone Purified talc Sucrose
Calendar pack, 'credit-card' format, 28 tablets
Prescription
Prescription
Bayer AG
Hormone replacement therapy (HRT) for the treatment of signs and symptoms of oestrogen deficiency due to the menopause (whether natural or surgically induced).
Package - Contents - Shelf Life: Calendar pack, 'credit-card' format - 28 tablets - 60 months from date of manufacture stored at or below 25°C - Calendar pack, 2x28, 'credit-card' format - 56 tablets - 60 months from date of manufacture stored at or below 25°C - Calendar pack, 3x28, 'credit-card' format - 84 tablets - 60 months from date of manufacture stored at or below 25°C
1969-12-31
PROGYNOVA ® CMI Vx1.0 1 PROGYNOVA ® (PRO·GUY·NO·VA) _estradiol valerate _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some of the common questions about Progynova tablets. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Progynova against the benefits they expect it will provide. IF YOU HAVE ANY CONCERNS ABOUT TAKING PROGYNOVA, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT PROGYNOVA IS USED FOR Progynova provides hormone replacement therapy (HRT) for the treatment of menopausal complaints after the cessation of monthly bleeding, or after surgical removal of the ovaries (oophorectomy). Progynova is only intended for short term use. Progynova contains estradiol valerate, a precursor of the hormone estradiol. During menopause, the estradiol production of the ovaries declines. Although menopause is natural, it often causes distressing symptoms, which are connected with the gradual loss of the hormones produced by the ovaries. Progynova replaces the hormone estradiol that the body no longer makes and prevents or relieves symptoms such as hot flushes, sweats, sleep disturbances, depressive moods, irritability, dizziness, headaches as well as vaginal dryness and burning. If you have not had your uterus removed (hysterectomy) your doctor will prescribe another hormone progestogen to take with Progynova. In addition, the loss of the hormones produced by the ovaries leads to thinning of the bones. In some women this effect may be extensive (postmenopausal osteoporosis) resulting in fractures of the bones in later life. Your doctor may also prescribe Progynova to prevent osteoporosis. PROGYNOVA IS NOT A CONTRACEPTIVE. It will not prevent you from falling pregnant. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may h Leggi il documento completo
PROGYNOVA DATA SHEET XV2.0, CCDS 14 Page 1 of 13 NEW ZEALAND DATA SHEET 1 PRODUCT NAME PROGYNOVA 1 mg tablets PROGYNOVA 2 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains 1mg of estradiol valerate- Progynova 1mg. One tablet contains 2 mg of estradiol valerate- Progynova 2 mg. 3 PHARMACEUTICAL FORM PROGYNOVA 1 mg: The memo-pack holds 28 beige, biconvex, round tablets, each containing 1.0 mg estradiol valerate. PROGYNOVA 2 mg: The memo-pack holds 28 light white, biconvex, round tablets, each containing 2.0 mg estradiol valerate. All tablets have a lustrous sugar coating and are approximately 7mm in diameter. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Hormone replacement therapy (HRT) for the treatment of signs and symptoms of estrogen deficiency due to the menopause (whether natural or surgically induced). Prevention of postmenopausal osteoporosis. 4.2 Dose and method of administration Hormonal contraception should be stopped when HRT is started and the patient should be advised to take non-hormonal contraceptive precautions, if required. Hysterectomised patients may start at any time. If the patient is still menstruating and has an intact uterus, a combination regimen of PROGYNOVA and a progestogen should begin within the first 5 days of menstruation (see below for Combination Regimen). Patients whose periods are very infrequent or with amenorrhoea or who are postmenopausal may start at any time, provided pregnancy has been excluded. Women changing from other HRT should complete the current cycle of therapy before initiating PROGYNOVA therapy. _Continuous Regimen _ It does not matter at what time of day the patient takes her tablet(s), but once she has selected a particular time, she should keep to it every day. If she forgets to take a tablet at the usual time, she may take it within the following 12 to 24 hours. If the treatment is discontinued for longer, irregular bleeding may occur. One tablet is taken daily (either one beige 1 mg tablet or one white 2 mg tablet). PROGYNOVA DA Leggi il documento completo